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Abstract
Objective SB2, a biosimilar to infliximab reference pro-
duct (INF), has an identical amino acid sequence and
similar physicochemical functional properties to its refer-
ence product. The primary objective of this study is to
demonstrate pharmacokinetic (PK) bioequivalence
between SB2 and EU-sourced INF (EU-INF), between SB2
and US-sourced INF (US-INF), and between EU-INF and
US-INF.
Methods This study was a randomized, single-blind,
three-arm, parallel group study in 159 healthy subjects. All
subjects received a single 5 mg/kg intravenous infusion of
study drug and then were observed for 10 weeks to study
PK, safety and immunogenicity. The primary PK parame-
ters were area under the concentration-time curve (AUC)
from time zero to infinity (AUCinf), AUC from time zero to
the last quantifiable concentration (AUClast) and maximum
concentration (Cmax). Bioequivalence for the primary PK
parameters was to be concluded using an analysis of
variance (ANOVA) if the 90 % confidence intervals (CIs)
for the ratio of geometric least squares means (LSMeans)
of the treatments compared were completely contained
within the pre-defined equivalence margin, 0.8–1.25.
Results All of the 90 % CIs for the geometric LSMean
ratios of primary PK parameters for each comparison were
within the pre-defined equivalence margin. The proportion
of subjects who experienced treatment-emergent adverse
events was comparable between treatments. The incidences
of anti-drug antibodies between the three treatments were
comparable.
Conclusion This study demonstrated biosimilarity of SB2
to its marketed reference products of infliximab in terms of
PK equivalence in healthy subjects. SB2 was generally
well tolerated and showed comparable safety and
immunogenicity profiles to the reference products (Clini-
calTrials.gov Identifier: NCT01922336).
Key Points
Single-dose pharmacokinetics of SB2 were shown to
be bioequivalent to those of reference products (EU-
sourced Remicade and US-sourced Remicade) in
healthy subjects, considered a sensitive population
for PK comparison.
Safety and immunogenicity of single-dose SB2 in
healthy subjects are comparable to those of reference
products.
1 Introduction
Infliximab, which is a genetically engineered chimeric
human/mouse glycosylated monoclonal antibody (mAb)
directed against tumour necrosis factor alpha (TNFa), acts
by neutralizing the proinflammatory action and regulatory
role of TNFa [1–3]. Infliximab was approved as Remi-
cade (Janssen Biotech Inc., Horsham, PA, USA) with the
indications including rheumatoid arthritis, adult Crohn’s
disease, paediatric Crohn’s disease, ankylosing spondylitis,
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psoriatic arthritis, ulcerative colitis, paediatric ulcerative
colitis and psoriasis [4].
Recently, Remsima (Celltrion Inc., Incheon, Korea),
using Remicade as the reference product, was approved
for use as an infliximab biosimilar in the EU by the
European Medicines Agency (EMA) [5]. As per EU
biosimilar requirements, the approval application included
a detailed and thorough characterization of the mAb and
non-clinical studies of the biosimilar with the reference
product [6]. This was complemented by a clinical phase I
study in ankylosing spondylitis patients and a clinical
phase III study in rheumatoid arthritis patients to establish
and confirm clinical biosimilarity [7, 8].
Samsung Bioepis Co., Ltd is developing SB2, a
biosimilar to Remicade, that is produced by recombinant
DNA technology and purified by various types of chro-
matography. In accordance with the regulatory agency
biosimilar guidelines, the development of SB2 had
involved biosimilarity studies starting with comparison of
the structural characteristics, physicochemical properties
and biological activities between SB2 and Remicade,
followed by demonstration of similar in vivo behaviour
between SB2 and its reference products [9, 10]. Based on
the in vitro and in vivo non-clinical study results, clinical
studies could be conducted to compare the clinical effi-
cacy, safety, and pharmacokinetics (PK) of SB2 with
those of infliximab reference products (INF). The aim of
this study was to compare the PK of SB2 and its refer-




Healthy female subjects of non-childbearing potential and
healthy male subjects aged 18–55 years were eligible for
participation in this study if bodyweight was between 60.0
and 94.9 kg and body mass index (BMI) was between 20.0
and 29.9 kg/m2. For inclusion, subjects had to be in good
health without any infectious disease including active or
latent tuberculosis as indicated by medical history, physi-
cal examination, vital signs, 12-lead electrocardiography
(ECG), serology, clinical laboratory tests, Quan-
tiFERON-TB Gold test (QIAGEN, Venlo, The Nether-
lands) and urine drug screening. These screening tests
were performed during a 3-week period prior to random-
ization. The nature and purpose of the study was fully
explained to each subject and written informed consent
was obtained from each subject before the subject was
enroled in the study.
2.2 Study Design
This study was a single-blind, parallel group, single-dose
study with three treatment groups, which were SB2 and
two infliximab reference products: EU-sourced Remicade
(EU-INF) and US-sourced Remicade (US-INF). All sub-
jects received a single dose of 5 mg/kg SB2, EU-INF or
US-INF by intravenous (IV) infusion for 120 min on the
first day of study and then were followed for 10 weeks
during which the PK, safety and immunogenicity mea-
surements were made. To avoid infusion-related reaction,
premedication with IV hydrocortisone (100 mg), oral
acetaminophen (1000 mg), and oral loratadine (10 mg)
were administered 30 min to 1 h prior to the infusion of
study drugs, which was adopted from a previous report
[11]. In case of infusion-related reactions, the infusion
could be temporarily discontinued or the infusion rate
decreased based on assessment of the investigators.
During the treatment period, subjects were hospitalized
in the PAREXEL Early Phase Clinical Unit (Berlin, Ger-
many) from 1 day before the study drug administration
until 3 days after administration for serial PK sampling and
close safety monitoring. After discharge, the subjects vis-
ited the site at 6, 8, 15, 22, 29, 43, 57, and 71 days after
administration. Safety was assessed by vital signs, clinical
laboratory tests, 12-lead ECG, and physical examinations.
Adverse events (AEs) recorded during the course of the
study were categorized by system organ class and preferred
terms using the MedDRA (Medical Dictionary for Regu-
latory Activities, version 16.0). Blood samples for
immunogenicity were collected to detect anti-drug anti-
bodies (ADAs) and neutralizing antibodies (NAbs) to
infliximab at pre-dose, 29 and 71 days after dosing. Blood
samples for immunogenicity evaluation were analysed
using an electrochemiluminescent immunoassay for ADA
detection and a functional cell-based assay for NAb
detection. The percent coefficient of variation (% CV) for
the negative control and high positive control for ADA
detection were 33.7 and 26.4 %, respectively.
2.3 Pharmacokinetic Evaluation
Blood samples for PK analysis were collected at pre-dose,
1 h after the start of infusion, the end of infusion, 3, 6, 12,
24, 48, 72, 120 h after the start of infusion and then at
weeks 1, 2, 3, 4, 6, 8 and 10 from the start of infusion.
Samples were kept frozen at -70 C or colder prior to
analysis. The serum concentration of infliximab was mea-
sured using an enzyme-linked immunosorbent assay
(ELISA) specific for the detection and quantification of
infliximab by TNFa (R&D Systems, Product No. 210-TA-
001MG/CF) coated in wells of an ELISA plate (PPD
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Bioanalytical Laboratory, Richmond, VA, USA). The
concentration limit of quantification was from 100 to
3200 ng/mL. Inter-assay precision measured as the % CV
were from 6.1 to 9.2 %, and the inter-assay accuracy
expressed as the percent difference of the mean value were
from 1.9 to 4.8 % within the quantification limit.
The PK parameter calculations were based on actual
sampling times and non-compartmental analysis methods.
The maximum concentration (Cmax) and time to reach Cmax
(Tmax) were obtained directly from the observed values.
The terminal elimination rate constant (kz) was estimated
at terminal phase by linear regression after loge-transfor-
mation of the concentrations. The terminal half-life (t)
was calculated as ln(2)/kz. The linear up/log down trape-
zoidal rule was used to obtain the area under the concen-
tration-time curve (AUC) from time zero to the last
quantifiable concentration (AUClast). AUC extrapolated to
infinity (AUCinf) was calculated as AUClast ? Clast/kz
(where Clast is the last quantifiable concentration). Clear-
ance (CL) was calculated as dose/AUCinf and volume of
distribution (Vd) was estimated as CL/kz. The PK param-
eter calculations were performed with Phoenix
WinNonlin version 6.2 (Certara, Princeton, NJ, USA).
2.4 Statistical Analysis
PK parameters were summarized in a descriptive manner
by treatment and immunogenicity results as overall, ADA
positive and ADA negative. An analysis of variance
model (ANOVA) was performed for comparison of pri-
mary PK parameters (AUCinf, AUClast and Cmax). The
difference in geometric least squares means (LSMeans) of
loge-transformed primary PK parameters between SB2
and EU-IFN, between SB2 and US-IFN and between EU-
IFN and US-IFN and the associated 90 % confidence
intervals (CIs) were determined. Back-transformation
provided the ratio of geometric means and the related
90 % CIs for the ratio of geometric LSMeans of pairwise
comparison were estimated. The bioequivalence of pri-
mary PK parameters were to be concluded when the 90 %
CI was within 0.8–1.25. All statistical analyses were
performed using SAS version 9.2 TS Level 2M3 (SAS-
Institute Inc., Cary, NC, USA).
3 Results
3.1 Subject Disposition
A total of 319 subjects were screened, of which 159 sub-
jects were randomized to receive one of three infliximab
study drugs (SB2, EU-INF, US-INF). None of the ran-
domized subjects discontinued from the study. The average
age, height, weight and BMI were generally comparable
across the three treatment groups (Table 1). Among the
randomized subjects, 150 subjects were male (49 subjects
in the SB2 treatment group, 51 subjects in the EU-INF
group and 50 subjects in the US-INF group) and nine
subjects were female (four subjects in the SB2 group, two
subjects in the EU-INF group and three subjects in the US-
INF group). The majority of the subjects were white. Two
subjects in the SB2 treatment group were not included in
the PK analysis due to the use of concomitant medication
for their AE treatment that could have influenced the PK of
infliximab, although their data were included in safety and
immunogenicity assessments.
3.2 Pharmacokinetic Results
The mean serum concentration curves on semi-logarithmic
scale for each treatment are presented in Fig. 1. Compar-
isons between SB2 and EU-INF, SB2 and US-INF, and
EU-INF and US-INF showed high similarity in the mean
serum concentration time profiles. In all cases, mean serum
concentration time profiles reached maximum exposure
between 2 and 6 h after start of infusion with a median
Tmax of approximately 3 h for SB2 and US-INF and of
approximately 2 h for EU-INF. Infliximab was slowly
cleared with an average t ranging from approximately
324–340 h for all treatment groups. The mean values of PK
Table 1 Baseline demographic
characteristics of enrolled
subjects
Treatment SB2 (N = 53) EU-INF (N = 53) US-INF (N = 53)
Gender (male) (%) 92.5 96.2 94.3
Race (White) (%) 96.2 98.1 98.1
Age (years) 40.7 ± 9.7 40.3 ± 9.7 39.4 ± 9.9
Height (cm) 178.5 ± 7.7 178.1 ± 6.0 178.6 ± 7.2
Weight (kg) 78.4 ± 8.7 80.5 ± 7.5 79.1 ± 8.3
BMI (kg/m2) 24.6 ± 2.1 25.4 ± 2.1 24.8 ± 2.1
Data are presented in either percentage (%) or mean ± standard deviation
BMI body mass index, EU-INF EU-sourced infliximab reference product, US-INF US-sourced infliximab
reference product
Comparative PK of Infliximab and Its Biosimilar 383
parameters (AUCinf, AUClast, Cmax, Tmax, Vd, t and CL)
were similar between treatments (Table 2).
For the PK similarity comparisons of SB2 with each of
the reference products (EU-INF or US-INF), the 90 % CI
for the test-to-reference ratios of AUCinf, AUClast and Cmax
were within the pre-defined equivalence margin of
0.8–1.25 (Table 3). The 90 % CIs of the ratios of AUCinf,
AUClast and Cmax were also within 0.8–1.25 for the com-
parison of EU-INF to US-INF.
To compare the immunogenicity influences on PK of
each study drug, sub-analyses based on the post-dose ADA
results were performed. The mean concentration of inflix-
imab in ADA-positive subjects compared with that of
ADA-negative subjects showed that the study drugs were
eliminated from blood circulation with relatively higher
clearance rates in ADA-positive subjects in all three
treatments (Fig. 1). The mean CL in ADA-positive subjects
after SB2, EU-INF and US-INF administration were 12.7,
13.6 and 12.9 mL/h, respectively, and those in ADA-neg-
ative subjects after SB2, EU-INF and US-INF administra-
tion were 9.4, 9.5 and 9.4 mL/h, respectively (Table 2).
The means for PK parameters including CL of each treat-
ment were comparable among each ADA-positive group
and -negative group.
3.3 Safety Results
A total of 124 treatment-emergent AEs (TEAEs) were
reported in 71 (44.7 %) subjects. Fifty TEAEs were
reported from 27 (50.9 %) subjects following SB2
administration, 36 TEAEs were reported from 21 (39.6 %)
subjects after EU-INF administration and 38 TEAEs were
reported from 23 (43.4 %) subjects after US-INF admin-
istration (Table 4). All reported TEAEs were of mild or
moderate severity, with the majority of reported TEAEs
being of mild severity, and the proportion of subjects with
TEAEs was comparable across the three treatment groups.
The most frequent TEAEs were nasopharyngitis and
headache, and no infusion-related reaction was reported.
Three serious adverse events (SAEs) were reported in two
subjects from the SB2 treatment group. One subject had a
concussion and a renal cyst ruptured, which were assessed
not to be related to study drug, and the other subject had a
Borrelia infection, which was assessed to be related to the
study drug. Those two subjects recovered without any
bFig. 1 Mean serum concentration-time profiles after single admin-
istration of infliximabs. a All subjects’ data included in the
pharmacokinetic analysis of SB2, EU-sourced infliximab reference
product, and US-sourced infliximab reference product; means of all
subjects and ADA subgroups for b SB2, c EU-sourced infliximab
reference product, and d US-sourced infliximab reference product.
Bars represent standard deviations of all subjects’ data including
ADA positive and ADA negative. ADA anti-drug antibody
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Table 2 Pharmacokinetic
parameters after a single dose of
SB2 or its reference products
PK parameter ADA SB2 EU-INF US-INF
Subjects All 51 53 53
Positive 23 20 20
Negative 28 33 33
AUCinf (lg*h/mL) All 38,703 ± 11,114 39,360 ± 12,332 39,270 ± 10,064
Positive 31,523 ± 7376 30,808 ± 5468 31,991 ± 7142
Negative 44,601 ± 10,218 44,543 ± 12,489 43,682 ± 9006
AUClast (lg*h/mL) All 36,862 ± 9133 37,022 ± 9398 37,368 ± 8332
Positive 31,052 ± 7038 30,463 ± 5244 31,413 ± 6433
Negative 41,635 ± 7856 40,998 ± 9166 40,976 ± 7256
Cmax (lg/mL) All 127.0 ± 16.9 126.2 ± 17.9 129.2 ± 18.8
Positive 123.9 ± 14.0 124.6 ± 14.5 128.2 ± 17.6
Negative 129.6 ± 18.8 127.2 ± 19.8 129.8 ± 19.7
Tmax (h) All 3.0 (2.0–6.0) 2.1 (2.0–6.1) 3.0 (2.0–6.1)
Positive 3.0 (2.0–6.0) 3.0 (2.0–6.1) 3.0 (2.0–6.1)
Negative 3.0 (2.1–6.0) 2.1 (2.0–6.0) 2.1 (2.0–6.0)
Vd (mL) All 4587 ± 1583 4846 ± 1287 4806 ± 1216
Positive 3643 ± 1473 3915 ± 1210 4110 ± 1263
Negative 5362 ± 1222 5411 ± 975 5228 ± 984
t (h) All 324.1 ± 148.7 339.5 ± 155.4 339.7 ± 135.6
Positive 218.3 ± 111.1 205.5 ± 77.2 236.8 ± 101.5
Negative 411.0 ± 116.3 420.6 ± 133.1 402.1 ± 114.7
CL (mL/h) All 10.9 ± 3.2 11.1 ± 3.0 10.7 ± 2.9
Positive 12.7 ± 3.4 13.6 ± 2.0 12.9 ± 2.8
Negative 9.4 ± 2.0 9.5 ± 2.5 9.4 ± 2.0
Data are presented as mean ± standard deviation except Tmax which is presented as median (minimum -
maximum)
ADA anti-drug antibody, AUCinf area under the concentration-time curve from time zero extrapolated to
infinity, AUClast area under the concentration-time curve from time zero to last quantifiable concentration,
CL clearance, Cmax maximum concentration, EU-INF EU-sourced infliximab reference product, PK
pharmacokinetic, t terminal half-life, Tmax time to reach Cmax, US-INF US-sourced infliximab reference
product, Vd volume of distribution
Table 3 Statistical comparison
of primary PK parameters
between test and reference
products
Test Reference PK parameter Geometric LS Mean Ratio (90 % CI)
Test Reference
SB2 EU-INF AUCinf (lg*h/mL) 37,162 37,705 0.986 (0.897–1.083)
AUClast (lg*h/mL) 35,702 35,930 0.994 (0.915–1.079)
Cmax (lg/mL) 125.9 125.1 1.007 (0.964–1.052)
SB2 US-INF AUCinf (lg*h/mL) 37,162 37,978 0.979 (0.894–1.072)
AUClast (lg*h/mL) 35,702 36,399 0.981 (0.904–1.064)
Cmax (lg/mL) 125.9 127.8 0.985 (0.942–1.030)
EU-INF US-INF AUCinf (lg*h/mL) 37,705 37,978 0.993 (0.908–1.086)
AUClast (lg*h/mL) 35,930 36,399 0.987 (0.913–1.067)
Cmax (lg/mL) 125.1 127.8 0.978 (0.935–1.024)
AUCinf area under the concentration-time curve from time zero extrapolated to infinity, AUClast area under
the concentration-time curve from time zero to last quantifiable concentration, CI confidence interval, Cmax
maximum concentration, EU-INF EU-sourced infliximab reference product, Geometric LSMeans geometric
least squares means, PK pharmacokinetic, Ratio geometric LSMeans ratio of PK parameters of test to those
of reference, US-INF US-sourced infliximab reference product
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sequelae. Vitals signs, ECG parameters and laboratory data
did not show any changes over time that might be con-
sidered to be related to the treatments. There were no
deaths or discontinuations due to AEs during the study.
3.4 Immunogenicity Results
The overall incidence of subjects with post-dose ADA to
infliximab was 47.2, 37.7 and 37.7 % in subjects treated
with SB2, EU-INF and US-INF, respectively. All three
subjects who were ADA positive at day 28 also had posi-
tive results from ADA test at day 71. There was no sta-
tistically significant difference in post-dose ADA incidence
across the three treatment groups (p = 0.432 between SB2
and EU-INF, p = 0.432 between SB2 and US-INF and
p = 1.000 between EU-INF and US-INF). The incidence
of post-dose NAb was comparable across the three treat-
ment groups (Table 5).
4 Discussion
The objective of this study was to compare the PK, safety
and immunogenicity of SB2 as an infliximab biosimilar
with those of infliximab reference products in healthy
subjects. The clinical PK study is considered to be essential
to demonstrate clinical biosimilar comparability [9], and
the most sensitive population that can reduce inter-indi-
vidual variation should be chosen. Healthy subjects are
considered to be a more homogeneous and hence more
sensitive population to study PK characteristics than
patients since patients can have various disease-related
factors which can influence the PK of study drugs. For
example, concomitant administration of methotrexate,
which is commonly used for autoimmune disease including
rheumatoid arthritis and psoriasis, can reduce the clearance
of infliximab compared with infliximab administered alone
[12].
Table 4 Summary of
treatment-emergent adverse
events
Treatment SB2 (N = 53) EU-INF (N = 53) US-INF (N = 53)
Any TEAEs 27 (50.9) 21 (39.6) 23 (43.4)
Mild severity TEAEs 26 (49.1) 19 (35.8) 18 (34.0)
Moderate severity TEAEs 7 (13.2) 5 (9.4) 5 (9.4)
Nasopharyngitis 6 (11.3) 4 (7.5) 3 (5.7)
Headache 5 (9.4) 6 (11.3) 7 (13.2)
Diarrhoea 3 (5.7) 2 (3.8) 1 (1.9)
Rhinitis 3 (5.7) 2 (3.8) 1 (1.9)
Dry skin 3 (5.7) 0 (0.0) 1 (1.9)
Each listed TEAE occurred regardless of causality in C5 % of subjects in any treatment
Data are presented as number of subjects (%)
EU-INF EU-sourced infliximab reference product, US-INF US-sourced infliximab reference product,
TEAEs treatment-emergent adverse events
Table 5 Incidence of anti-drug
antibodies and neutralizing
antibodies to infliximab
Parameter Time point Result SB2, n/n’ (%) EU-INF, n/n’ (%) US-INF, n/n’ (%)
ADA Pre-dose Positive 0/53 (0.0) 0/53 (0.0) 0/53 (0.0)
Negative 53/53 (100.0) 53/53 (100.0) 53/53 (100.0)
Day 29 Positive 2/53 (3.8) 0/53 (0.0) 1/53 (1.9)
Negative 51/53 (96.2) 53/53 (100.0) 52/53 (98.1)
Day 71 Positive 25/53 (47.2) 20/53 (37.7) 20/53 (37.7)
Negative 28/53 (52.8) 33/53 (62.3) 33/53 (62.3)
NAb Day 29 Positive 1/2 (50.0) 0/0 0/1 (0.0)
Negative 1/2 (50.0) 0/0 1/1 (100.0)
Day 71 Positive 14/25 (56.0) 14/20 (70.0) 7/20 (35.0)
Negative 11/25 (44.0) 6/20 (30.0) 13/20 (65.0)
ADA anti-drug antibody, EU-INF EU-sourced infliximab reference product, n number of subjects with each
assessment result at each time point, n’ number of subjects with available assessment results at each time
point, NAb neutralizing antibody, US-INF US-sourced infliximab reference product
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Equivalence of the PK between the test and reference
products was based on the CIs for the primary PK variables
AUCinf, AUClast and Cmax in relation to the accepted range
of 0.8–1.25. To meet the requirements of both the EMA
and FDA, comparison data between SB2 and EU-INF and
between SB2 and US-INF demonstrate the evidence of
equivalence in PK between SB2 and each of the two test
products, respectively [9, 10]. The PK equivalence between
EU-INF and US-INF would provide scientific justification
to use EU-INF, which is not licensed in the USA, as the
sole active comparator in a phase III clinical trial.
Although a cross-over design for comparative clinical
studies greatly reduces the variability in PK, a cross-over
design with infliximab was not feasible considering the
long t. The t of this study in healthy subjects is
approximately 2 weeks for all studied infliximabs, which is
similar to previous infliximab PK studies in patients and
can be considered long enough not to apply the cross-over
design [1, 12, 13]. Moreover, ADAs to the study drug from
the first administration could influence the PK after a
second administration [14, 15]. Therefore, a parallel design
for infliximab PK comparison would be more suit-
able considering the study purpose.
PK sub-analyses according to the post-dose ADA status
were performed to explore the relationship between
immunogenicity of study drugs and PK. Within each
treatment, systemic exposure of infliximab in ADA-posi-
tive subjects tended to be lower than in ADA-negative
subjects. Means of AUCs in ADA-positive subjects were
23–31 % lower than those of ADA-negative subjects in
each treatment. It is known that anti-infliximab antibody
can have an influence on the PK of infliximab by changing
the drug clearance rates [4]. A recent PK modelling study
showed that mean CL was 47.1 % higher in patients pos-
itive for antibodies to infliximab compared with those who
were negative [15]. There is a limitation to comparing the
historical data and current study results since the previous
study results were obtained from patients, while this study
was performed in healthy subjects. However, the differ-
ences in mean CL between post-dose ADA-positive and
ADA-negative subjects in this study were comparable with
previous modelling study results (35, 43 and 37 % for SB2,
EU-INF and US-INF, respectively). Though there is an
immunogenicity influence on PK of infliximab, the 90 %
CIs for the geometric LS Mean ratio of all primary PK
parameters for each ADA-negative subject group and
ADA-positive subject group between SB2 and EU-INF,
SB2 and US-INF, and EU-INF and US-INF were within the
0.8–1.25 criteria (data are not shown). This PK comparison
per ADA results could confirm the PK equivalence
between treatments regardless of immunogenicity. There-
fore, it is concluded that there is no difference in
immunogenicity and the PK influence of post-dose ADA in
SB2, EU-INF and US-INF.
Overall, PK equivalence between the proposed inflix-
imab biosimilar, SB2, and reference products EU-INF or
US-INF was demonstrated, and the immunogenicity
impacts on PK were also similar between treatment groups
in this phase I study in healthy subjects. A clinical con-
firmatory phase III study is in progress to compare the
efficacy and safety, including immunogenicity, between
SB2 and EU-INF in patients with rheumatoid arthritis.
5 Conclusion
In conclusion, this clinical study in healthy subjects
showed pharmacokinetic equivalence between SB2 and its
marketed reference products of infliximab. No significant
difference in terms of safety and immunogenicity profiles
was found across the treatment groups.
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